Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Haleon PLC - Surrey, England-based consumer healthcare products - Provides a historical earnings breakdown based its new reporting structure ahead of interim results on July 31. Haleon at a capital markets day back in May said it would start to report in six product categories: Oral Health, Vitamins, Minerals & Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health & Other. This splits out Respiratory Health and Therapeutic Skin Health & Other from what had been Digestive Health & Other. Within Haleon’s £11.23 billion in total revenue in 2024, Oral Health, which includes the Sensodyne brand, was the biggest of these segments at £3.31 billion, followed by Pain Relief, with the Advil and Panadol brands, at £2.56 billion. Haleon says its geographic split remain unchanged.
Current stock price: 376.70 pence, down 0.3% on Monday morning in London
12-month change: up 15%
Copyright 2025 Alliance News Ltd. All Rights Reserved.